0001141788 false 0001141788 2022-10-19 2022-10-19 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

 

FORM 8-K

 

 

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported): October 19, 2022

 

Health Discovery Corporation

(Exact name of registrant as specified in charter)

 

GA   333-62216   74-3002154
(State of incorporation)   (Commission File Number)  

(IRS Employer

Identification No.)

 

 

2002 SUMMIT BLVD, SUITE 300    
ATLANTA, GA   30319
(Address of principal executive offices)   (Zip Code)

  

(404) 566-4865

(Registrant’s telephone number, including area code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act.

 

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act.

 

☐ Pre-commencement communications pursuant to Rule 14d–2(b) under the Exchange Act.

 

☐ Pre-commencement communications pursuant to Rule 13e–4(c) under the Exchange Act.

 

Securities registered pursuant to Section 12(g) of the Act:

Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock, no par value HDVY N/A

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

   

 

 

 

Item 5.02Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.

 

On October 19, 2022, Jim Murphy notified George H. McGovern, III, Chairman and Chief Executive Officer of Health Discovery Corporation (the “Company”) in an email that he intended to resign from his position as a director of the Company. Mr. Murphy stated that his resignation was due entirely to personal reasons. Mr. Murphy further stated that he had no disagreements with the Company or any of its directors, officers or other personnel.

 

Item 9.01Financial Statements and Exhibits

 

(d)Exhibits

 

99.1Jim Murphy’s Resignation Email
104Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

  HEALTH DISCOVERY CORPORATION

 

 

 

 

    
Dated:  October 26, 2022 By: /s/ George H. McGovern, III  
   

George H. McGovern, III

Chairman & Chief Executive Officer

 

 

 

 

 

 

 

 

 

 2 

 

Health Discovery (CE) (USOTC:HDVY)
Gráfica de Acción Histórica
De Oct 2024 a Nov 2024 Haga Click aquí para más Gráficas Health Discovery (CE).
Health Discovery (CE) (USOTC:HDVY)
Gráfica de Acción Histórica
De Nov 2023 a Nov 2024 Haga Click aquí para más Gráficas Health Discovery (CE).